BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Genstruct announces new collaboration with Pfizer in drug safety
News | 02. 20. 2008
Selventa
CAMBRIDGE, Mass., February 20, 2008 /PRNewswire/ -- Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology announced today that it has entered into a Master Research Agreement with Pfizer designed to cover current and future collaborations. The first collaboration under this new agreement is in the area of preclinical drug safety, focusing initially on a systems biology analysis of underlying mechanisms of drug-induced liver injury.
